This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $77.89 in the latest trading session, marking a +0.13% move from the prior day.
Top Stock Reports for Bank of America, Qualcomm & ConocoPhillips
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp. (BAC), Qualcomm Inc. (QCOM) and ConocoPhillips (COP).
Pfizer (PFE) Begins Pediatric Study on COVID Pill Paxlovid
by Zacks Equity Research
Pfizer's (PFE) Paxlovid is the first oral antiviral pill to be studied in a pediatric clinical study.
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
What's in Store for These 3 Big Pharma Outperformers in 2022?
by Kinjel Shah
J&J (JNJ), AbbVie (ABBV) and Merck (MRK) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Alpine (ALPN) Down on FDA Partial Clinical Hold on Cancer Study
by Zacks Equity Research
The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
FDA Nods to Bristol Myers' (BMY) Opdivo for Additional Indication
by Zacks Equity Research
Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.
Merck (MRK) Outperforms Industry, What's in Store for 2022?
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $77.83 in the latest trading session, marking a +0.88% move from the prior day.
WHO Recommends Merck (MRK) Oral Pill for Certain COVID Patients
by Ekta Bagri
Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.
Nektar (NKTR) Q4 Earnings Top, Three Bempeg Filings Due in 2022
by Zacks Equity Research
Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates
by Zacks Equity Research
Mirati Therapeutics (MRTX) reports wider-than-expected fourth-quarter loss. Sales miss estimates.
Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss
by Zacks Equity Research
Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.
Moderna (MRNA) Q4 Earnings Top, COVID-19 Vaccine Brings $7B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine sales beat expectations. The company delivers 297 million doses of its COVID-19 vaccine during the fourth quarter. Stock gains in pre-market.
The Zacks Analyst Blog Highlights Merck & Co, Shopify, Intercontinental Exchange, Barrick Gold Corp and NXP Semiconductors
by Zacks Equity Research
Merck & Co, Shopify, Intercontinental Exchange, Barrick Gold Corp and NXP Semiconductors are included in this analyst blog.
AstraZeneca (AZN) Enhertu Effective in HER2-Low Breast Cancer
by Zacks Equity Research
AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-low metastatic breast cancer.
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the fourth-quarter earnings call that reduce its dependence on Spikevax.
Top Research Reports for Merck, Shopify & Intercontinental Exchange
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Shopify Inc. (SHOP), and Intercontinental Exchange, Inc. (ICE).
Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong
by Zacks Equity Research
Exelixis (EXEL) beats on both earnings and revenues in the fourth quarter. Both figures increase on a year-over-year basis.
Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA
by Zacks Equity Research
The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.
Is Invesco Defensive Equity ETF (DEF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DEF